{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"31.9","value":"6.7"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"41.0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Sunitinib -- Cohort A"},{"description":"Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Sunitinib -- Cohort B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"While patient remains on treatment, up to 30 weeks","title":"Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}